{
  "id": 684692,
  "title": "Entera Bio at Canaccord Genuity: oral osteoporosis push advances",
  "url": "https://urgent.news/2026/08/12/entera-bio-at-canaccord-genuity-oral-osteoporosis-push-advances",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-12T17:46:18.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/entera-bio-at-canaccord-genuity-oral-osteoporosis-push-advances-93CH-4855827"
  },
  "original_language": "en",
  "account": "On Wednesday, August 12, 2026, biotech company Entera Bio utilized Canaccord Genuity's 46th Annual Growth Conference to discuss the accelerated development of its lead osteoporosis drug, EB613. The firm highlighted a shorter study timeline aligned with FDA requirements and a recent $275 million financing round, though its shares fell 4.83% to $2.855, trading below its prior close. Despite the stock's decline, Entera Bio boasts a $493 million market capitalization and a 97% return over the past half-year, as reported by InvestingPro. Analysts remain optimistic, with a consensus price target of $9, indicating potential upside of more than 200% from the current level. Entera Bio's CEO, Miranda Toledano, emphasized the company's years-long collaboration with regulators to refine the EB613 program, aiming to transition the drug into a Phase III oral anabolic treatment for osteoporosis. Osteoporosis, described by Toledano as a \"most common metabolic bone disease globally\" and \"the most under-treated yet diagnosed chronic progressive disease,\" remains largely untreated. Entera Bio's strategy centers on democratizing anabolic therapy through its N-Tab platform, which converts peptides into oral tablets. This platform addresses challenges in delivering large, hydrophilic peptides through the digestive system, such as maintaining activity and stability. EB613, containing teriparatide, a 34 amino acid sequence of native parathyroid hormone, boasts a short half-life, facilitating pulsatile bone-building effects. The U.S. alone has around 10-12 million diagnosed osteoporosis cases, with 54 million Americans at risk of bone loss. Globally, Entera Bio estimates 200 million osteoporosis patients. The FDA alignment, announced on June 22, 2026, resulted from a multi-year review process initiated in February 2022, culminating in a Type A meeting in July 2025 and a clinical amendment in Q1 2026. The planned Phase III trial, expected to enroll 750 post-menopausal women at fracture risk, will be a 12-month, double-blind, placebo-controlled study, followed by an open-label extension through 24 months. Half of the patients will receive EB613 alone, while the other half will receive standard antiresorptive therapy. Entera Bio's 505(b)(2) pathway comparison with FORTEO, a listed drug, aims to demonstrate the drug's efficacy through total hip BMD as a surrogate efficacy endpoint. The company's oral format could alleviate injection burdens, dosing frequency issues, and patient acceptance challenges associated with current osteoporosis treatments. Entera Bio's primary care, gynecology, endocrinology, rheumatology, and orthopedic surgery market approach aims to reach patients beyond current therapy limitations. Despite a volatile stock with a beta of 1.4 and a 52-week trading range of $0.91 to $4.20, Entera Bio's aggressive timeline and market potential offer growth prospects for investors.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Zevra Therapeutics at Canaccord Genuity: growth plan widens",
        "url": "https://urgent.news/2026/08/11/zevra-therapeutics-at-canaccord-genuity-growth-plan-widens",
        "published": "2026-08-11T15:48:30.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}